Pharmacokinetic disposition of anagliptin, a novel dipeptidyl peptidase-4 inhibitor, in rats and dogs

European Journal of Drug Metabolism and Pharmacokinetics

Volumn 38, Issue 2, 2013, Pages 87-96

  Furuta, Shinji ^a   Tamura, Miyuki ^a   Hirooka, Hiroko ^a   Mizuno, Yukie ^a   Miyoshi, Mika ^a   Furuta, Yoshiyuki ^a  

^a SANWA KAGAKU KENKYUSHO CO LTD   (Japan)

Author keywords

Anagliptin; Distribution; DPP 4 inhibitor; Excretion; Metabolism; Pharmacokinetics

Indexed keywords

ANAGLIPTIN; ANAGLIPTIN C 14; CYCLOSPORIN A; MULTIDRUG RESISTANCE PROTEIN; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG EXCRETION; DRUG FORMULATION; DRUG HALF LIFE; DRUG POTENTIATION; DRUG STRUCTURE; GLOMERULUS FILTRATION RATE; HYDROLYSIS; HYDROXYLATION; LIQUID CHROMATOGRAPHY; MALE; NONHUMAN; OXIDATION; PHARMACODYNAMICS; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; TANDEM MASS SPECTROMETRY; TISSUE DISTRIBUTION;

ANIMALS; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DOGS; MALE; PYRIMIDINES; RATS; RATS, SPRAGUE-DAWLEY; TISSUE DISTRIBUTION;

EID: 84878666921     PISSN: 03787966     EISSN: 21070180     Source Type: Journal    
DOI: 10.1007/s13318-013-0119-z     Document Type: Article

References (21)

1. Ahren B (2009) Clinical results of treating type 2 diabetic patients with sitagliptin, vildagliptin or saxagliptin - diabetes control and potential adverse events. Best Pract Res Clin Endocrinol Metab 23:487-498
2. Arimori K, Kuroki N, Hidaka M, Iwakiri T, Yamsaki K, Okumura M, Ono H, Takamura N, Kikuchi M, Nakano M (2003) Effect of P-glycoprotein modulator, cyclosporin A, on the gastrointestinal excretion of irinotecan and its metabolite SN-38 in rats. Pharm Res 20(6):910-917
3. Caron N, Kramp R (1999) Measurement of changes in glomerular filtration rate induced by atrial natriuretic peptide in the rat kidney. Exp Physiol 84:689-696
4. Duez H, Cariou B, Staels B (2012) DPP-4 inhibitors in the treatment of type 2 diabetes. Biochem Pharmacol 83(7):823-832
5. 14C]anagliptin, a novel dipeptidyl peptidase-4 inhibitor, in humans. Xenobiotica. Oct 18: [Epub ahead of print]
6. Halimi S, Schweizer A, Minic B, Foley J, Dejager S (2008) Combination treatment in the management of type 2 diabetes: focus on vildagliptin and metformin as a single tablet. Vasc Health Risk Manag 4(3):481-492
7. Holst JJ, Deacon CF (2005) Glucagon-like peptide-1 mediates the therapeutic actions of DPP-IV inhibitors. Diabetologia 48:612-615
8. Idris S, Donnelly R (2007) Dipeptidyl peptidase-IV inhibitors: a major new class of oral antidiabetic drug. Diabetes Obes Metab 9:153-165
9. Kato N, Oka M, Murase T, Yoshida M, Sakairi M, Yamashita S, Yasuda Y, Yoshikawa A, Hayashi Y, Makino M, Takeda M, Mirensha Y, Kakigami T (2011) Discovery and pharmacological characterization of N-[2-({2-[(2S)-2- cyanopyrrolidin-1-yl]-2-oxoethyl}amino)-2-methylpropyl]-2-methylpyrazolo[1,5-a] pyrimidine-6-carboxamide hydrochloride (anagliptin hydrochloride salt) as a potent and selective DPP-IV inhibitor. Bioorg Med Chem 19(23):7221-7227
10. Komatsu R, Matsuyama T, Namba M, Watanabe N, Itoh H, Kono N, Tarui S (1989) Glucagonostatic and insulinotropic action of glucagon-like peptide I-(7-36)-amide. Diabetes 38:902-905
11. Lambeir AM, Durinx C, Scharpé S, De Meester I (2003) Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Crit Rev Clin Lab Sci 40(3):209-294
12. Mentlein R (1999) Dipeptidyl-peptidase IV (CD26) - role in the inactivation of regulatory peptides. Regul Pept 85:9-24
13. Mest HJ, Mentlein R (2005) Dipeptidyl peptidase inhibitors as new drugs for the treatment of type 2 diabetes. Diabetologia 48:616-620
14. Nauck MA, Bartels E, Orskov C, Ebert R, Creutzfeldt W (1993) Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations. J Clin Endocrinol Metab 76:912-917
15. Orskov C, Holst JJ, Nielsen OV (1988) Effect of truncated glucagon-like peptide-1 [proglucagon-(78-107) amide] on endocrine secretion from pig pancreas, antrum, and nonantral stomach. Endocrinology 123:2009-2013
16. Sharma MD (2010) Role of saxagliptin as monotherapy or adjunct therapy in the treatment of type 2 diabetes. Ther Clin Risk Manag 25(6):233-237
17. Stumvoll M, Goldstein BJ, van Haeften TW (2005) Type 2 diabetes: principles of pathogenesis and therapy. Lancet 365(9467):1333-1346
18. Sunami Y, Yoshioka N, Hayashi I, Ishida T (2007) Safety, tolerability, pharmacokinetics and pharmacodynamics of SK-0403, a Novel DPP-IV inhibitor, in healthy Japanese subjects. American Diabetes Association 67th Scientific Session, Chicago, IL, June 22-26, Poster 0482-P [Online] Available at: http://professional.diabetes.org/Content/Posters/2007/p0482-P.pdf. Accessed on 11 Sept 2012
19. Thornberry NA, Gallwitz B (2009) Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4). Best Pract Res Clin Endocrinol Metab 23(4):479-486
20. Wang E, Meier DJ, Sandoval RM, Von Hendy-Willson VE, Pressler BM, Bunch RM, Alloosh M, Sturek MS, Schwartz GJ, Molitoris BA (2011) A portable fiberoptic ratiometric fluorescence analyzer provides rapid point-of-care determination of glomerular filtration rate in large animals. Kidney Int 31:1-6
21. Zerilli T, Pyon EY (2007) Sitagliptin phosphate: a DPP-4 inhibitor for the treatment of type 2 diabetes mellitus. Clin Ther 29:2614-2634